ArticleMolecular neurobiology2026
A Study on the Effects of Intranasally Administered Liquid Crystalline Nanoparticles Loaded with Salvianolic Acid B in Vascular Dementia.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Salvianolic acid B (SalB) is a bioactive polyphenol with therapeutic potential for vascular dementia (VD), but poor penetration across the blood-brain barrier (BBB) and low bioavailability restrict its clinical translation. To address these problems, a SalB-loaded liquid crystalline nanoparticle delivery system (SalB-LCN) was constructed and systematically characterized in terms of its physicochemical properties. Meanwhile, an intranasal administration strategy was employed to bypass the BBB, and the therapeutic effects of SalB-LCN on VD were systematically evaluated. The results showed that SalB-LCN possessed favorable morphology and sustained-release properties, enabling stable encapsulation and continuous release of SalB. In vitro experiments demonstrated that SalB-LCN exhibited good biocompatibility and could alleviate oxidative damage in neuronal cells. In a bilateral common carotid artery occlusion-induced rat model of VD, SalB-LCN significantly improved learning and memory abilities, alleviated hippocampal neuronal morphological damage, and exhibited good in vivo biosafety. Further studies showed that SalB-LCN markedly lowered reactive oxygen species levels, suppressed IL-1β and IL-18 production in hippocampal tissues, and reduced cell death as well as lactate dehydrogenase activity. In addition, SalB-LCN also suppressed NLRP3/Caspase-1/GSDMD signaling. In conclusion, intranasal delivery of SalB-LCN improved brain delivery by facilitating transport across the BBB and conferred neuroprotection against VD through modulation of oxidative stress, inflammation, and NLRP3/Caspase-1/GSDMD signaling, highlighting its translational potential as a nanomedicine-based therapeutic strategy.
Indexed as
Identifiers
42481908What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.